https://www.selleckchem.com/pr....oducts/shin1-rz-2994
Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.Recently, the growing environmental concerns and economic demands have driven the need to develop effective solutions for the treat
Like
Comment
Share
